ca1576(2023 ASH｜中国研究最全汇总，看这一篇就够了！)

一年一度的美国血液学会（ASH）年会是全球血液学领域最受瞩目的国际学术盛会之一，每年都吸引着来自世界各地的专家学者。2023年第65届ASH年会将于12月9日-12日在美国圣迭戈召开，会议将公布最顶尖的血液学领域研究摘要，探讨如何改善患者的管理和治疗、探寻新的治疗方案。

近年来，中国临床研究发展迅速，中国在世界血液学领域的影响力也日益增加。作为中国疫情政策开放后的第一届ASH年会，相信今年我国会有更多的专家学者踏上ASH年会的舞台，分享他们的研究成果、观点和经验。

根据当地时间11月2日上午9:00 ASH官网公布的摘要，医脉通小编检索到今年我国专家共有64篇研究入选Oral Abstracts ，466篇研究入选Poster Abstracts，相比去年增长47%！医脉通特将研究相关信息整理如下，以飨读者。

Oral Abstracts

摘要号标题/报告人及单位7Bromodomain Protein BRD4 Is a Transcriptional Repressor of Terminal Erythropoiesis By Interacting with EHMT1/2
Meng Zhang，浙江大学医学院附属第一医院
10A Mediator Switch Tunes Transcription Pausing to Drive Erythropoiesis
Hsiang-Ying Lee，北京大学
55Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study
杨莉，上海交通大学医学院附属同仁医院
83Loss of DDX3X Function Promotes CLL Progression By Facilitating NOTCH1 mRNA Translation
苗毅，江苏省人民医院
101A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy
胡永仙，浙江大学医学院附属第一医院
117Discovery of BCL-XL Heterobifunctional Degrader with Potentially Improved Therapeutic Window and Minimal Platelet Toxicity for Hematological Malignancies
Yang Xie，北京星亢原生物科技有限公司
123Development and Validation of Deep Learning Model for Diagnosis and Subtypes Differentiation of Myeloproliferative Neoplasms Using Clinical Data and Digital Pathology
Zhongxun Shi，江苏省人民医院
139Mitochondrial tRNA Pseudouridylation Regulates Erythropoiesis Via the mTOR Signaling Pathway: Implications for Mlasa and Treatment Strategies
Yajing Chu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
142The ATF4-RPS19BP1 Axis Modulates Ribosome Biogenesis to Promote Erythropoiesis
Zhaofeng Zheng，中国医学科学院血液病医院（中国医学科学院血液学研究所）
157An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial
Harinder Gill，香港大学
188Clinical Implications of CSF-Ctdna in CNS Involvement of Newly Diagnosed Diffuse Large B Cell Lymphoma: An Improvement of Diagnosis, Treatment and Evaluation
梁金花，江苏省人民医院
189Diagnostic and Prognostic Value of Circulating Cell-Free DNA in Cerebrospinal Fluid and Plasma in Newly Diagnosed Diffuse Large B Cell Lymphoma
李炳宗，苏州大学附属第二医院
218Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial
陆佩华，北京陆道培医院
234Short-Term Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation in B-Cell Acute Lymphoblastic Leukemia with Low Leukemia Burden
Hang Zhang，四川大学华西医院
239CD7 Chimeric Antigen Receptor T-Cell Therapy Bridging to Allogeneic Hematopoietic Stem Cell Transplantation Remarkably Improved Long-Term Disease-Free Survival in Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma
李智慧，北京高博博仁医院
278Gpibα Caar-T Cells Induce Autoreactive B Cells Elimination to Treat Immune Thrombocytopenia
梅恒，华中科技大学同济医学院附属协和医院
279Iguratimod Regulates CD4 T-Cell Homeostasis and Function By Restoring PINK1/Parkin-Mediated Mitophagy in Immune Thrombocytopenia
Yuxiu Chen，北京大学人民医院
281Notch1 Regulates Hepatic Thrombopoietin Production
乔建林，徐州医科大学
286The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease
Yeu-Chin Chen，台湾三军总医院
289CD74 Leukemia-Associated Macrophages Supporess T Cell Immune Surveillance and Promote Leukemic Cell Growth in Acute Myeloid Leukemia
Guo Qiu，南方医科大学南方医院
304A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
洪煌明，四川省肿瘤医院
305Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)
宋玉琴，北京大学肿瘤医院
306A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas
宋玉琴，北京大学肿瘤医院
320Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)
杨威，中国医科大学附属盛京医院
366Deciphering the Impact of Donor Telomere Length on Allogeneic Transplantation Outcomes: Telomere Length Matters More Than Age
Hengwei Wu，浙江大学医学院附属第一医院
410Targeting G3BP2 Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment Via ELF1-MCL1 Axis
陈智香，福建医科大学附属协和医院
471Mega-Dose Decitabine Intensified Regimen Is More Effective at Eliminating Pre-HSCT Measurable Residual Disease Compared to the Bu/Cy Regimen: A Multicenter Prospective Phase II Study
Hao Zheng，北京大学人民医院
474The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML
Xiaoyu Zhang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
476Clonal GZMK CD8 t Cells Are Identified As a Hallmark of Pathogenesis of Cgvhd-Induced Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
肖浩文，浙江大学医学院附属邵逸夫医院
480SLC16A7 Facilitates aGVHD through Regulating Calcium Influx and Lipid Metabolism of CD4 T Cells
Xiaoxuan Lai，苏州大学附属第一医院
524CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL
Xiyue Xu，天津医科大学肿瘤医院
572KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients
张凤奎，中国医学科学院血液病医院（中国医学科学院血液学研究所）
586IL1RAP-Specific T Cell Engager (TCE) Antibody Efficiently Depletes Acute Myeloid Leukemia (AML) Leukemic Stem Cells (LSCs)
张仪，浙江大学医学院附属第一医院
609IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity
周可树，河南省肿瘤医院
621Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis
Harinder Gill，香港大学
627HMR Mutations Drive Poor Prognosis in Myelofibrosis Patients with Lower JAK2V617F Allele Burden but Not in Those with Higher Allele Burden: Results of a Multicenter Study
Yu-Hung Wang，国立台湾大学医学院
650Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Identical Peripheral Blood Hematopoietic Stem Cell Transplantation
Hang Zhang，四川大学华西医院
659Comparative Study for Haplo, MSD and MUD Allo-Hcts for Core-Binding Factor AML Patients in CR2: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
叶逸山，浙江大学医学院附属第一医院
660Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
叶逸山，浙江大学医学院附属第一医院
686Integrin αvβ8-Mediated Activation of TGF-β1 Is Involved in Regulating the Sustained Response after TPO-Ras Withdrawal in ITP Patients
Min Xu，华中科技大学同济医学院附属协和医院
687Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial
Xu Yanmei，中国医学科学院血液病医院（中国医学科学院血液学研究所）
688The Therapeutic Efficacy of CD19 Chimeric Antigen Receptor T Cells in Immune Thrombocytopenia Model
Yun Wang，山东大学齐鲁医院
729Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial
Li Gao，苏州大学附属儿童医院
736A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses
张会来，天津医科大学肿瘤医院
761Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1
李春蕊，华中科技大学同济医学院附属同济医院
778Safety and Efficacy of Human Amniotic Epithelial Stem Cells Eye Dropin Ocular Chronic Graft-Versus-Host Disease
Xianjing Cheng，陆军军医大学第二附属医院（新桥医院）
803Prednisone Plus Ivig Compared with Prednisone for Immune Thrombocytopenia during Pregnancy
Yuxiu Chen，北京大学人民医院
827Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study
弓晓媛，中国医学科学院血液病医院（中国医学科学院血液学研究所）
829Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)
Yunxiang Zhang，上海交通大学医学院附属瑞金医院
834Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase 2 Clinical Trial
Xiaoping Li，中国人民解放军联勤保障部队第九二〇医院
846Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-Resistance in T-Cell Acute Lymphoblastic Leukemia
Jingliao Zhang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
857A Phase II Study of the Efficacy and Safety of the Srmt (Sintilimab, Rituximab, Methotrexate, and Temozolomide) Regimen in Newly Diagnosed Primary Central Nervous System Lymphoma
曾志勇，福建医科大学附属第一医院
867Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study
江倩，北京大学人民医院
869Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study
江倩，北京大学人民医院
879The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma
Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
889Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL
Lei Yu，上海优卡迪生物医药科技有限公司
891Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults
Mingming Zhang，浙江大学医学院附属第一医院
969Venetoclax Combined with Daunorubicin and Cytarabine (2 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
索晓慧，邯郸市中心医院
970Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial
卢静，苏州大学附属第一医院
1022Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
杜鹃，上海长征医院
1025C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
梁爱斌，上海市同济医院（同济大学附属同济医院）
1037Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible
Yi-Jiun Su，台湾林口长庚医院
1039Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT
胡永仙，浙江大学医学院附属第一医院
1041Haploidentical Hematopoietic Cell Transplantation Combined with an Unrelated Cord Blood Unit for Adult Acute Myeloid Leukemia Results in Improved Survival Compared to Haploidentical Hematopoietic Cell Transplantation: Results of a Multicenter, Randomized, Phase III Trial
Biqi Zhou，苏州大学附属第一医院

Poster Abstracts

摘要号标题/报告人及单位1165Clinical Characteristics, Genomic Profiling and Outcomes of Langerhans Cell Histiocytosis in Adults with Single System Multifocal Disease
Hong-Xiao Han，北京协和医院
1167Myelodysplastic Syndrome Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Study of 15 Cases in a Single Center
Yue Song，苏州大学附属第一医院
1175Caebv Disease Originates from Infected Hematopoietic Stem Cells
王晶石，首都医科大学附属北京友谊医院
1176A Respective Analysis of EBV DNA Status in T/NK Cell Lymphoma Associated-Hemophagocytic Lymphohistiocytosis
Lulu Wang，浙江大学医学院附属第一医院
1181Virus-Specific CD8 Stem Memory T Lymphocytes Display Enhanced Anti-Virus Responses
Xunhong Cao，北京大学人民医院
1185Pgam1 Regulate Adaptive NK Cells in Anti-Viral and Anti-Tumor Response
Juan Xie，北京大学人民医院
1205N-Acetylneuraminic Acid Induces Vascular Endothelial Dysfunction through Targeting Mcu/SQSTM1 Pathway and Attenuates Atherosclerosis
Limei MA，重庆医科大学
1206CM313, a Novel Anti-CD38 Antibody, As a Potential Treatment for Primary Immune Thrombocytopenia: A Phase II Trial
Yunfei Chen，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1207Baricitinib in Combination with High-Dose Dexamethasone As First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
赵芃，北京大学人民医院
1213The Combination of Intravenous Immunoglobulin (IVIG) and Low Does Recombinant Human Thrombopoietin (rhTPO) for the Management of Corticosteroid/IVIG Monotherapy-Resistant Immune Thrombocytopenia in Pregnancy
Yun He，北京大学人民医院
1216Effect of Hetrombopag Combined with Rhtpo in Patients with Severe Immune Thrombocytopenia
殷杰，苏州大学附属第一医院
1217Eltrombopag Plus Rhtpo for Corticosteroid-Resistant or Relapsed ITP: A Prospective Observed Study
付海霞，北京大学人民医院
1219The Role of Gpiba in Control of Megakaryocyte Reactivity to Thrombopoietin
Fengjiao Han，山东大学齐鲁医院
1229Discovery of BT-114143, a Novel and Potent Small-Molecule Plasminogen Inhibitor for Hyperfibrinolysis
唐军，赛诺哈勃药业(成都)有限公司
1233Thrombosis Caused By a Novel Coagulation Factor IX Mutation (FIX Shanghai II)
Wenman WU，上海交通大学医学院附属瑞金医院
1236Proteomics Reveals the Potential Pathogenesis of Coagulopathy in Patients with Hematological Malignancies Following CAR-T Therapy
Yingying Li，华中科技大学同济医学院附属协和医院
1268The Proactive Diagnostic Value of Thrombin-Antithrombin Complex and Antithrombin III in Disseminated Intravascular Coagulation
Qiuyu Guo，山东大学齐鲁医院
1278Risk Factors of Venous Thromboembolism in Lymphoma Patients: A Meta-Analysis
Cuiting Jiang，重庆大学附属肿瘤医院
1305Unrevealing Hematopoietic Reconstruction Discrepancies after Allo-UCBT and Allo-PBSCT at Single Cell Resolution
Qing Li，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1313Nynrin Preserves Hematopoietic Stem Cell Function Via the Ppif-Mediated Mitochondrial Permeability Transition
周成芳，重庆医科大学生命科学研究院
1316The Relationship between Telomere Length and Epigenetic Aging with Hematologic Diseases Risk: A Multivariable Mendelian Randomisation Study
Yang Li，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1343The Efficacy of Hetrombopag Combined with Cyclosporine a in Patients with Transfusion-Dependent Non-Severe Aplastic Anemia
何广胜，江苏省人民医院
1345Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia
Wei Zhang，山东大学齐鲁医学院
1348Efficacy and Safety of Recombinant Thrombopoietin Combined with Immunosuppressive Therapy for Primary Treatment of Severe Aplastic Anemia: A Single-Center, Open-Label, Randomized, Clinical Trial
Wenrui Yang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1350The Change of Complement Deposition after Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria Patients
Menglu Zhang，北京协和医院
1351A Preliminary Report of Clinical Study on Immunosuppressive Therapy Combined with Avatrombopag As the First-Line Treatment for Severe Aplastic Anaemia in Elderly Patients
Lei Ye，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1353Clinical Features and Outcomes in Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia with STAT3 Mutation
Xiaoqing Liu，南京中医药大学附属南京医院
1366Clinical Features and Monitoring of Germline CEBPA-Mutated Carriers
潘莉莉，福建医科大学附属协和医院
1367Phase Separation of PML/RARa Microspeckles Governs Transcriptional Dysregulation through Genomic Rewiring of BRD4 in Acute Promyelocytic Leukemia
Yi Zhang，上海交通大学医学院附属瑞金医院
1372Kdm6a Modulates Hematopoiesis and Leukemogenesis Via Demethylase-Dependent Epigenetic Programming
Huiqiao Chen，浙江大学医学院附属邵逸夫医院
1373PGK1 Represents a Therapeutic Target for Pediatric Acute Myeloid Leukemia Via Regulating c-Myc/SLC7A5/mTOR Pathway
Yijun Wu，苏州大学附属儿童医院
1379Ebf1 Is Involved in Primitive Myelopoiesis and Contributes in Leukemia Pathogenesis
Rongtao Xue，南方医科大学南方医院
1414Partner Gene Associated Trinary Fusion and Orchestration of Multiple Molecular Events in Acute Promyelocytic Leukemia with Variant Rara Fusion Genes
陈佳琦，北京陆道培医院
1432Modulating Metabolic Reprogramming By Phosphoglycerate Dehydrogenase (PHGDH) Inhibitors in Omipalisib-Refractory AML
Chi-Yang Tseng，国立台湾大学
1442Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma
丁宁，北京大学肿瘤医院
1462The Different Impacts of an MRD-Guided Protocol on Relapse of Childhood Acute Lymphoblastic Leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013
Hsi-Che Liu, MD，马偕纪念医院
1466The Pediatric-Inspired Regimen Improved Quality and Quantity of Life for Patients with Acute Lymphoblastic Leukemia，Beyond Age, Risk Stratification, and Hematopoietic Stem Cell Transplantation
Junjie Chen，南方医科大学南方医院
1481Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia
Xiaolu Zhu，北京大学人民医院
1485Identification of Characteristics and Prognostic Impact of FUS-ERG and AML1-MTG16 Fusion Genes in Adult AML Patients
Ziyue Zhou，浙江大学医学院第一附属医院
1501Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial
薛胜利，苏州大学附属第一医院
1504Frontline Combination of 3rd Generation TKI Olverembatinib and Blinatumomab for Ph /Ph-like ALL Patients
Ting Zhang，zhangtashley@hotmail.com, Guangzhou, China
1505Efficacy and Safety of Avatrombopag in the Treatment of Chemotherapy-Induced Thrombocytopenia in Children with Acute Lymphoblastic Leukemia: A Retrospective Study
Libai Chen，南方医科大学南方医院
1506Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial
薛胜利，苏州大学附属第一医院
1517Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia
周泽平，昆明医科大学第二附属医院
1518Venetoclax Combined with Hypomethylation Agents As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia - Priliminary Results from a Real World Study in China
戴海萍，苏州大学附属第一医院
1522ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the "3 7" Regimen in Newly Diagnosed AML: A Real-World Experience from South China
翁建宇，广东省人民医院
1524Cladribine Combined with Homoharringtonine and Cytarabine Achieves a High Remission Rate in Adult Patients with De Novo Acute Myeloid Leukemia, Especially for Adverse-Risk Group: A Prospective, Single Center, Single-Arm, Phase 2 Study
孙杰，浙江大学医学院附属第一医院
1525Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Wen-Jing Yu, 北京大学人民医院
1527Idarubicin Plus Azacitidine Venetoclax As Induction Therapy Achieved High Remission in Elderly Fit- Acute Myeloid Leukemia Patients: Preliminary Results of a Phase II Study
Xinjie Chen，上海交通大学医学院附属瑞金医院
1528Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia
Qian Wu，苏州大学附属第一医院
1530Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study
Sijian Yu，南方医科大学南方医院
1561Role of ITGA5 in Malignant Proliferation and Infiltration of Acute Myeloid Leukemia
Xinqi Li，武汉大学中南医院
1566Advances in Acute Myeloid Leukemia Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5, and International Consensus Classification
陈雪，北京陆道培医院
1568Heterogeneity and Differentiation Patterns of pDC Cells in pDC-AML: A Novel Perspective from Single-Cell RNA Sequencing
Xingcheng Yang，华中科技大学同济医学院附属同济医院
1576The Ingenious Multiple Efficacies of the Integrated Gene Fragment of Torque Teno Mini Virus in Orchestrating Promyelocytic Leukemogenesis Via Hijacking Rara
周晓苏，北京陆道培医院
1578Targeting HDAC9 Contributes to Degradation of MLL Fusion Oncoproteins in KMT2A-Rearranged Acute Myeloid Leukemia
Yutong Zhou，浙江大学医学院附属第一医院
1592PET Tracer-Based Glucose Uptake Predicts Clinical Response to Induction Therapy in Acute Myeloid Leukaemia
曾辉，暨南大学附属第一医院
1607One Tube 23 Color Full Spectral Flow Cytometry Panel in Detecting Minimal Residual Disease in Pediatric B-Cell Acute Lymphoblastic Leukemia
Kefei Wu，上海交通大学医学院附属上海儿童医学中心
1610Deciphering the Structural Variants in B Cell Acute Lymphoblastic Leukemia By Optical Genome Mapping
刘铭，北京陆道培医院
1611CD38 Is a Functional Partner of CD9 in B-Cell Precursor Acute Lymphoblastic Leukemia
Po Yee Chung，香港中文大学儿科学系
1612Clinical Implications of Germline Predisposition Gene Variants in Patients with Refractory or Relapsed B Acute Lymphoblastic Leukemia
Zhao Defeng，北京高博博仁医院
1628Extrachromosomal Circular DNA Drives the Progression of DLBCL through Activating the Sting Pathway
Zijuan Wu，江苏省人民医院
1634Targeting the Cgas-Sting Pathway Inhibits the Progression and Enhances the Chemotherapy Efficacy of Peripheral T-Cell Lymphoma
金晖，江苏省人民医院
1649Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
Li Yuxi，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1652Lactate-Mediated Histone H3K9 Lactylation Facilitates Tumorigenesis of T-Cell Lymphoma Via Activation of SFXN1 Expression
Zhuoya Yu，山东大学附属医院
1658Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma
曲昌菊，苏州大学附属第一医院
1677PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial
苏航，解放军总医院第五医学中心
1682Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up
宋玉琴，北京大学肿瘤医院
1685A Predictive Model Based on Machine Learning for Early Progression/Relapse of Follicular Lymphoma
Yingyue Liu，山东大学附属医院
1687A Prospective Phase II Study of Radiotherapy Followed By Tiselizumab Combined with R-CHOP in the Untreated Follicular Lymphoma Patients with Bulky Disease in China
李维，天津市肿瘤研究所
1689PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study
黄慧强，中山大学肿瘤防治中心（中山大学附属肿瘤医院）
1690Efficacy and Safety of Chemotherapy (DDGP vs VIPD) Followed Radiotherapy Vs Radiotherapy Followed Chemotherapy (DDGP vs VIPD) Vs Radiotherapy Alone for Newly Diagnosed Early Stage Extranodal Natural Killer/T Cell Lymphoma: Final Results of a Prospective, Multicenter, Randomized, Controlled Clinical Trial
张明智，郑州大学第一附属医院
1694Anti-PD-1 Antibody Sintilimab in Combination with Anlotinib and Pegaspargase As a Highly Effective Salvage Regimen for the Treatment of Relapsed or Refractory Natural Killer /T-Cell Lymphoma
陶荣，复旦大学附属肿瘤医院
1696High Rates of Remission with the Initial Treatment of Oral Selinexor Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes Analysis of a Multi-Center Phase II Study in China
范磊，江苏省人民医院
1709Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma
Xiaomei Yang，山东大学附属儿童医院
1719GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
宋玉琴，北京大学肿瘤医院
1722A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies
刘薇，中国医学科学院血液病医院（中国医学科学院血液学研究所）1732Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study
李志铭，中山大学肿瘤防治中心（中山大学附属肿瘤医院）
1736A Multicenter, Prospective Clinical Study of the R-CDOP Regimen in Previously Untreated Non-Hodgkin Lymphoma with High Tumor Burden
Wei Guo，吉林大学第一医院
1744Cyclin D1-Positive Expression Associated with Prognostic Significance and Clinicopathological Characteristics By Paving the Way for Proliferation in Diffuse Large B-Cell Lymphomas
Xiping Liang，重庆大学附属肿瘤医院
1745Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations
王黎，上海交通大学医学院附属瑞金医院
1746CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients
Rui Liu，北京高博博仁医院
1747Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients
Yuhong Ren，复旦大学附属中山医院
1754Treatment of Relapsed/Refractory Hgbcl and Bukitt’s Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation
Sung-Soo Yoon，首尔大学医院
1758Preliminary Results of a Phase Ⅱ Study of Lenalidomide Combined with Immunochemotherapy in Patients with Primary Central Nervous System Lymphoma
Shuna Yao，郑州大学附属肿瘤医院
1763Ratio of Circulating CD8 T Lymphocytes to M-MDSCs (CD8MMR): A Novel Prognostic Predictor for Treatment-Naïve DLBCL Patients
Hao-Yuan Wang，台北荣民总医院
1769Simplified Geriatric Assessment-Albumin: The Modified Tool for Older Diffuse Large B-Cell Lymphoma in China
Xiaoya Yun，北京医院
1796Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology
许娜，南方医科大学南方医院
1797Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
陈苏宁，苏州大学附属第一医院
1798Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph ALL)
Elias Jabbour，M.D.安德森癌症中心
1801Dynamic Single-Cell RNA-Seq Reveals Mechanism of Selinexor-Resistance in Chronic Myeloid Leukemia
Zhengxu Sun，江苏省人民医院
1804Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?
杨森，北京大学人民医院
1807TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients
许娜，南方医科大学南方医院
1814Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)
张仪，浙江大学医学院附属第一医院
1824Sex-Specific Impact on Disease Outcome and Mutational Landscape in Essential Thrombocythemia
Chen Jia，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1829First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study
徐泽锋，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1836Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing in Pre-Fibrotic Primary Myelofibrosis Patients
黄健，浙江大学医学院附属第一医院
1848Single Cell Analyses Indicate SRSF2 and TET2 Co-Mutation Results in Skewed Haematopoiesis in Myelodysplastic Syndromes
梁洋，中山大学肿瘤防治中心（中山大学附属肿瘤医院）
1856Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial
Liya Ma，浙江大学医学院附属第一医院
1859Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)
佟红艳，浙江大学医学院附属第一医院
1865AK117 (anti-CD47 monoclonal antibody) in Combination with Azacitidine for Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): AK117-103 Phase 1b Results
佟红艳，浙江大学医学院附属第一医院
1869Red Blood Cell Transfusion Dependence Is Associated with Greater Healthcare Resource Utilization, Higher Medical Cost, and Poorer Prognosis in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Observation Study Result
Ji-Hyun Kim，韩国百时美施贵宝医疗事务部
1875Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms
Junying Wu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1878Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification
Hsin-Yu Lu，国立台湾大学医学院
1900Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials
周可树, 郑州大学附属肿瘤医院
1920Monitoring Minimal Residual Disease in Patients with Multiple Myeloma By Tracking Serum M-Protein Using Mass Spectrometry
Huishou Fan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1923IRF4-BLOC1S5, the First Genomic Fusion Gene Identified in the TEMPI Syndrome
阎骅，上海交通大学医学院附属瑞金医院
1926Circulating Exosomal miRNA Signature As a Potential Risk Factor for DNA Virus Infection in Patients with Multiple Myeloma
Xin Chen，中南大学湘雅三医院
1929IGF2BP1 Promotes Multiple Myeloma with Chromosome 1q Gain Via Increasing CDC5L Expression in an m6A-Dependent Manner
Jiadai Xu，复旦大学附属中山医院
1955Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma
Jingyu Xu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1967Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma
Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
196811q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH
Jiao Lu，苏州大学附属第一医院
1975Retrospective Analysis of Four Frailty Assessment Tools in Elderly Patients with Multiple Myeloma
Yujun Li，黔西南州人民医院
1978A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Mingyuan Sun，中国医学科学院血液病医院（中国医学科学院血液学研究所）
1983Clinical Characteristics of Patients with CRS without Elevated IL-6 Levels after CAR-T Cell Therapy for Multiple Myeloma
Hailang Xu，徐州医科大学附属医院
1988Neurotropin Alleviates Bortezomib-Induced Neurotoxicity Via Microglial Neuroinflammation
冯永怀，遵义医科大学附属医院
2006Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab
傅卫军，上海长征医院（现单位：同济大学附属上海市第四人民医院）
2032A Comparative Study of Clinical Characteristics, Cytogenetic Abnormalities and Outcomes Among Multiple Myeloma, Primary Light-Chain Amyloidosis and Multiple Myeloma with Concurrent AL Amyloidosis
Chenqi Yu，复旦大学附属中山医院
2038Applying Machine Learning to Support Early Diagnosis of Light-Chain Amyloidosis: A Combination of Knowledge-Based Approach with Data-Driven Approach
刘扬，北京大学人民医院
2048G-CSF Induces MAIT Cells to Exert Anti-Intestinal Gvhd Effects Dependent on CXCR6 Mediated Chemotaxis
Gao Mengge，北京大学人民医院
2049Hspa5 Deficiency Blocks Intestinal Enterocyte Differentiation in Graft-Versus-Host Disease
Fei Gao，浙江大学医学院附属第一医院
2053Long Noncoding RNA NEAT1 Regulates Acute Graft-Versus-Host Disease By Promoting Macrophage M1 Polarization through JNK Pathway
Ran Zhang，郑州大学第一附属医院
2061Dual Co-Stimulation with CD28 and ICOS Enhances T Cell Activation and Optimizes CAR-T Cell Antitumor Activity
梅恒，华中科技大学同济医学院附属协和医院
2062Bio-Orthogonally Redirected Bispecific Lentiviral Vectors for In Vivo CAR-T Cell Generation
梅恒，华中科技大学同济医学院附属协和医院
2072T-Cell Receptor-Engineered T Cells Targeting FLT3-D835 Mutation-Derived Neoantigens in Acute Myeloid Leukemia
Weijun Zhou，南方医科大学珠江医院
2080Epigenetic Reprogramming By Histone Deacetylase Inhibitors Improves CAR-T Cell Functions
Tianning Gu，浙江大学医学院附属第一医院
2094A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma
肖希斌，浙江大学医学院附属第二医院
2100Prophylactic or Preemptive Donor-Derived CD19 CAR-T Cell Infusion for Preventing Relapse in High-Risk B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation
Wenyi Lu，河南省人民医院
2106A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults
Xiaomei Zhang，南开大学医学院
2107High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma
张弦，北京陆道培医院
2108Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma
郑彪，邦耀生物
2109Gene-Edited Universal CD7 Chimeric Antigen Receptor T Cells for Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
刘芳，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2111Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL
胡永仙，浙江大学医学院附属第一医院
2115Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy
梁爱斌，上海市同济医院（同济大学附属同济医院）
2116BCMA CAR-T-Cell Therapy in Combination with Long-Term Pomalidomide Is a Safe and Effective Treatment for Relapsed/Refractory Multiple Myeloma
李昕，中南大学湘雅三医院
2117Adoptive Transfer of CMV-Specific TCR-T Cells for the Treatment of CMV Infection after Haploidentical Hematopoietic Stem Cell Transplantation
马超，中国人民解放军总医院
2142Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL
Bin Xue，上海市同济医院（同济大学附属同济医院）
2144Donor T Cell Infusions Limit Novel Immune Checkpoint Therapy in Pancreatic Cancer: Implications for Adoptive T Cell Therapy
Po-Chih Hsu，台北慈济医院
2147Comparing Phenotyping, Gene Expression, and Function of T Lymphocytes before Mobilization Chemotherapy Versus after Stem Cell Harvesting in Patients with B Cell Lymphoma and Multiple Myeloma
Sheng-Hsuan Chien，国立阳明交通大学
2154Risk Factors and Prognostic Model for II-IV aGVHD in Patients with Engraftment Syndrome after Haploidentical Hematopoietic Stem Cell Transplantation
王颂，北京大学人民医院
2155CD7 CAR-T Therapy Followed By a Second Transplant for T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients Who Relapsed after a Prior Transplant
曹星玉，北京陆道培医院
2160New Aplastic Anemia Preconditioned with Fludarabine, Thiotepa, Cyclophosphamide, and Anti-Thymocyte Globulin
叶宝东，浙江中医药大学附属第一医院2163Clinical Characteristics, Prognosis Factors and Metagenomic Next-Generation Sequencing Diagnosis of Mucormycosis in Patients with Hematologic Diseases: A Single-Center Retrospective Study
Jieru Wang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2168Successful Use of Haploid Hematopoietic Stem Cell Transplantation for Severe Glanzmann's Thrombasthenia
Shuran Wang，苏州大学附属儿童医院
2184Iron Dys-Homeostasis Contributed to Liver Gvhd after Allogeneic Hematopoietic Stem Cell Transplantation
Shufen Wang， 浙江大学医学院附属邵逸夫医院
2194Donor Macrophage Pyroptosis Contributed to the Development of aGVHD
Xueyan Sun，北京大学人民医院
2195Explorations of Post-DLI Low-Dose Cyclophosphamide for Preventing Severe aGVHD
Xinhui Zheng，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2201Microbiome Signature of non-Responder to Fecal Microbiota Transplantation in Patient with Steroid-Refractory Chronic Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation
Kaibo Yang，南方医科大学南方医院
2212Trametinib Maintenance in Patients with RAS Mutated Hematologic Malignancy Undergoing Allogeneic Haematopoietic Stem-Cell Transplantation: A Retrospective Transplant Study
李智慧，北京高博博仁医院
2222Clinical Study on the Efficacy and Safety of Peg Rhg CSF for Autologous Hematopoietic Stem Cell Mobilization in Lymphoma and Multiple Myeloma锛歛 Randomized Controlled, Multicenter Clinical Study
Lingqian Zhang，重庆大学附属肿瘤医院
2228Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm
Bingqian Jiang，浙江大学医学院附属第一医院
2229Allo-HSCT Improved Outcome of High Risk ALL in Pediatric-Inspired PDT-ALL-2016 Cohort
Junjie Chen，南方医科大学
2243Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors
Bingqian Jiang，浙江大学医学院附属第一医院
2267Preclinical Efficacy and Mechanism for a Novel BTK-Protacs Against Mantle Cell Lymphoma
费越，天津医科大学肿瘤医院
2278Establishment of a Dynamic Ctdna Monitoring System to Predict the Prognosis of CAR-T Cell Therapy in R/R B-NHL Patients
Linghui Zhou，浙江大学医学院附属第一医院
2282Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy
唐晓文，苏州大学附属第一医院
2448Dynamic Changes in Lysine Succinylation As Important Regulators of Erythropoiesis
Jing Liu，中南大学湘雅二医院
2457Erythrocyte Intracellular Adenosine Regulates Oxygen Release Combating Tissue Hypoxia, Inflammation and Fibrosis
Changhan Chen，中南大学湘雅医院
2461An Optimized Human Erythroblast Differentiation System Reveals Cholesterol-Dependency of Robust Production of Cultured Red Blood Cells Ex Vivo
Senquan Liu，中国科学技术大学附属第一医院
2539The Protective Role of Tubular Epithelial Cells Produced Fms-like Tyrosine Kinase Receptor 3 Ligand in Acute Kidney Injury
Na Li，中山大学附属第七医院
2543Clinical Characteristics of Shwachman–Diamond Syndrome in China — Result from Childhood Bone Marrow Failure Diseases Register of China Alliance for Blood Diseases(cBMFR-CABD)
Yang Wan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2557Neutralizing Antibody Responses in Patients with Hematological Malignancies after Omicron Infection: A Multicenter, Prospective Cohort Study in China
Li Jun，重庆大学附属肿瘤医院
2558MAIT Cell Proliferation Is a Potential Early Diagnosis Marker for Blood Stream Infection in AML Patients
Yuping Fan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2562Platelet-Derived TGF-β1 Induces Functional Reprogramming of Myeloid-Derived Suppressor Cells in Immune Thrombocytopenia
Yu Hou，山东大学齐鲁医院
2565The Alternative Splicing of Lck in Treg Induction in Immune Thrombocytopenia
Nan Jiang，山东大学齐鲁医院
2576Mice Lacking α-Actinin-1 in Megakaryocytes Display the Feature of Thrombocytopenia and Impair Platelet Functions
Jiansong Huang，浙江大学医学院附属第一医院
2582Tacrolimus and Danazol Combination As a Second-Line Therapeutic Strategy for Steroid-Resistant or Relapsed Immune Thrombocytopenia: A Prospective, Randomized, Multicenter, Open-Label Study
安倬玉，北京大学人民医院
2585High Dimensional Single-Cell Profiling Identifies Immune and Metabolic Heterogeneity in Immune Thrombocytopenia
杨丽萍，北京大学人民医院
2586Bone Marrow CD8 Tissue-Resident Memory T Cell Promote B Cell Differentiation and Inhibit Platelet Production in Patients with Immune Thrombocytopenia
Qi Feng，山东大学齐鲁医院
2588Terbutaline Modulates Macrophage Homeostasis and Macrophage-T-Cell Interactions in Immune Thrombocytopenia
吴冶君，北京大学人民医院
2589The Combination of Iguratimod and Danazol Versus Danazol As a Treatment of Corticosteroid-Resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-Label Trial
朱晓璐，北京大学人民医院
2590Long-Term Eltrombopag in Children with Chronic Immune Thrombocytopenia: A Single-Center Extended Real-Life Observational Study in China
Zhifa Wang，首都医科大学附属北京儿童医院
2594Real-World Evidence of Avatrombopag for the Treatment of Immune Thrombocytopenia Intolerant or Ineffective to Eltrombopag/Hetrombopag
Hong Tian，苏州大学附属第一医院
2597Clinical and Genetic Characteristics of 30 Patients Misdiagnosed As Having ITP with Non-Muscle Myosin Heavy Chain 9-Related Disease (MYH9-RD): A Retrospective Analysis in China
王雅丹，华中科技大学同济医学院附属协和医院
2615Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-Label, Multicenter, Phase 2 Study
薛峰，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2623Acquired Hemophilia a: A Single-Center Study of 165 Patients
Dandan Yu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2624Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis
Yuan Xu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2628Single-Dose Rituximab Plus Glucocorticoid Versus Cyclophosphamide Plus Glucocorticoid in Patients with Newly Diagnosed Acquired Hemophilia a: A Multicenter, Open-Label, Randomized Clinical Trial
刘薇，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2673MED16 Negatively Regulates Erythropoiesis and Myelopoiesis through Modulation of Chromatin Accessibility
Si Xie，北京大学生命科学学院
2675Nlrc3 Signaling Is Indispensable for Hematopoietic Stem Cell Emergence Via Notch Signaling in Vertebrates
Shuyang Cai，浙江大学医学院附属第一医院
2677Iguratimod Could Correct the Defective IL-35-Mediated Megakaryopoiesis in Immune Thrombocytopenia
蔡璇，北京大学人民医院
2683The RNA Helicase DHX16 Is Required for the Maintenance of Hematopoietic Stem Cells
李志刚，重庆医科大学生命科学研究院
2075VLA-4 Agonist Enhances the Capacity of HSC Engraftment and Immune Reconstitution
宋献民，上海市第一人民医院
2717Impaired Immunosuppressive Effect of Bone Marrow Mesenchymal Stem Cell-Derived Exosomes on T Cells in Aplastic Anemia
Shichong Wang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2718Differences between Peripheral and Bone Marrow Lipidomics in Patients with Severe Aplastic Anemia and Its Finding in Predicting the Early Immunosuppressive Therapy Response
Zexing Sun，浙江省中医院
2721Comparison between Hetrombopag and Eltrombopag Combined with IST As First-Line Treatment for Severe Aplastic Anemia
杨文睿，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2725Optimized Rabbit Antithymocyte Globulin Protocol Plus Sequential Cyclosporine and Levamisole Regimen for Newly Diagnosed Severe Aplastic Anemia: A Single-Arm, Single-Centre, Prospective, Phase 2 Trial
Meili Ge，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2748ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy
Jie Zhou，上海市同济医院（同济大学附属同济医院）
2750IKZF2 Specifically Participates in AML1-ETO Mediated Blockage of Myeloid Differentiation
Yu Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2754Histone Methyltranferase SETD8 Stimulates Proliferation and Anti-Apoptotic Effect in Acute Myeloid Leukemia through Epigenetically Upregulation of CXCR4
Zelong Cui，山东大学齐鲁医院
2757Pre-Existing Chromatin States Regulate KLF4 Binding to Eliminate Leukemia Stem Cells
Ting Lu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2763Epigenetic Silencing of CD9 Shapes a New Mechanism to Render Differentiation Block and Immune Evasion in Pediatric Acute Myeloid Leukemia
Yaqun Xu，香港中文大学
2807Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations
Yihan Wang，深圳市塔吉瑞生物医药有限公司
2812Transcriptomics and Time-Course Proteomics Reveal Pclaf As an Inducer of Resistance Against Pevonedistat in Diffuse Large B-Cell Lymphoma
Tiange Lu，山东省立医院
2822Preclinical Study of DZD8586, a Non-Covalent LYN/BTK Dual Inhibitor with Excellent BBB Penetration, for the Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL)
白瑜，迪哲(上海)医药有限公司
2823YAP1-Dependent Promotion of Downstream Transcription through BRD4 Mediates Selinexor Resistance in Diffuse Large B-Cell Lymphoma
王晓璇，天津医科大学肿瘤医院
2826Combination of CDK4/6 Inhibitor Palbociclib and PI3K Inhibitor Idelalisib Synergistically Induces an Anti-Tumor Effect in B-Cell Lymphoma and Overcomes Ibrutinib Resistance
Dingyao Hu，北京大学肿瘤医院
2836Prognostic Features of CD9 in Childhood Acute Lymphoblastic Leukemia – a Retrospective Analysis of a Nation-Wide Multicenter Study in China
Kathy Yuen Yee Chan，香港中文大学
2840Combination of Liposomal Mitoxantrone, Venetoclax, Homoharringtonine, and Olverembatinib (HQP1351) (MVHO) in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML): Case Series
胡文婷，上海交通大学医学院附属上海儿童医学中心
2849Comparison of Autologous, Matched Sibling, and Alternative Donor Stem Cell Transplant Outcomes for Acute Myeloid Leukemia Patients in First Remission: A Propensity Score Matching Study
姜尔烈，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2850Homozygous CEBPA Mutations Predict Favorable Outcomes in AML Patients
潘莉莉，福建医科大学附属协和医院
2861Efficacy and Safety of Avatrombopag on Thrombocytopenia after Chemotherapy in Acute Leukaemia
Xiaoli Chen，江苏省中医院（南京中医药大学附属医院）
2867Clinical Characteristics, Genetic Profile and Prognosis of Adult Acute Myeloid Leukemia with NUP98 Rearrangement
祝洪明，上海交通大学医学院附属瑞金医院
2869Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial
索珊珊，浙江大学医学院附属第一医院
2879To Reverse Sensitization By Co-Administration of Bortezomib and Rituximab with Conventional Chemotherapy for Patients Who Developed Neutralizing Hypersensitivity Reactions Against Asparaginase
陈长城，上海交通大学医学院附属上海儿童医学中心
2890Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center
吴萍，广东省人民医院
2895Venetoclax Combining with Homoharringtonine，Daunorubicin and Cytarabine (HAD) As Induction Treatment in Newly Diagnosed Adult Acute Myeloid Leukemia Patients
Zhangsong Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2900A Phase I Study of Venetoclax Combined with Homoharringtonine, Cytarabine, and G-CSF for the Treatment of Pediatric De Novo Acute Myeloid Leukemia
Shengqin Cheng，苏州大学附属儿童医院
2901Venetoclax Combined with HMA Versus CAG Based Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis
Xiaonan Lin，南方医科大学珠江医院
2905Decitabine Combined with Low-Dose Chemotherapy Is Effective in the Treatment of Pediatric Refractory/Relapsed Acute Myeloid Leukemia
Liyan Fan，苏州大学附属儿童医院
2908A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
齐军元，中国医学科学院血液病医院（中国医学科学院血液学研究所）
2912Venetoclax Combining with Homoharringtonine，Daunorubicin and Cytarabine (HAD) As Induction Treatment in Newly Diagnosed Adult Acute Myeloid Leukemia Patients
Jiajia Pan，浙江大学医学院附属第一医院
2920Effect and Mechanism of NL-101 Combined with Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia
Xia Jiang，宁波大学附属人民医院
2925Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms
王华锋，浙江大学医学院附属第一医院
2935ALDH3A2 Regulates Ferroptosis By Participating in Fatty Acid Synthesis and Finally Lead to Chemotherapy Resistance in Acute Myeloid Leukemia
Yun Huang，南方医科大学南方医院
2946Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All-Trans Retinoic Acid and Arsenic Trioxide
陈丽，上海交通大学医学院附属瑞金医院
2949Trinary Fusion with Ligand Binding Domain Castration Is Crucial in Rarg-Driven APL and Render Unresponsive to ATRA Via Allosteric Disability Mechanism
周晓苏，北京陆道培医院
2962FLT3-ITD Induces Immune Escape in AML Via up-Regulating CD47 Expression and Decreased Phagocytic Ability of Macrophages
梁洋，中山大学肿瘤防治中心（中山大学附属肿瘤医院）
2965Novel Role of DHX15 in Modulating AML/ETO9a Spliced Variant Production in AML/ETO AML
王雪纯，福建医科大学附属协和医院
2971Metabolomic Insights into the Pathogenesis and Prognostic Potential of Adult Acute Lymphoblastic Leukemia
Junyu Wang，上海交通大学医学院附属瑞金医院
2973The Tetraspanin CD9 Shapes Glucocorticoid Sensitivity in Pediatric B-Precursor Acute Lymphoblastic Leukemia
Chi Zhang，香港中文大学
2975Drug Response Profiling of Childhood T-Cell Acute Lymphoblastic Leukemia to Inform Functional Precision Medicine
Guanglan Lin，香港中文大学
2979Selinexor Synergizes CX4945 on Anti-Tumor Effect By Targeting XPO1/Ikros/c-Myc Signaling in T-Cell Acute Lymphoblastic Leukemia
Min Sui，东南大学附属中大医院
2994Paired Circulating Tumor DNA in Cerebrospinal Fluid and Peripheral Blood: Reliable Technology for Diagnosing and Monitoring Primary and Secondary Central Nervous Lymphoma
Xinyu Zhu，上海市同济医院（同济大学附属同济医院）
3008Navigating the Blood-Brain Barrier: An Anti-CD19 Modified-Exosome Delivery System for Precise Targeting of CNS Lymphoma
李炳宗，苏州大学附属第二医院
3010Combination of Selinexor with BTK Inhibitor for Central Nervous System Diffuse Large B-Cell Lymphoma, Possible Mechanisms and Therapeutic Potential Exploration
Li Li，大连医科大学附属第二医院
3013HIV-Related Diffuse Large B Cell Lymphoma Influences on T Cell Exhaustion
Tingting Jiang，重庆大学附属肿瘤医院
3022Integrative Genomic and Transcriptomic Analysis Reveals Genetic Alterations Associated with the Early Progression of Follicular Lymphoma
高凤华，天津医科大学肿瘤医院
3024Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China
宋玉琴，北京大学肿瘤医院
3033Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton’s Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
宋玉琴，北京大学肿瘤医院
3038The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma
Yanshan Huang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
3039Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
曹欣欣，北京协和医院
3048Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma
Jie Zha，厦门大学附属第一医院
3049The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study
杨萍，北京大学第三医院
3065Causal Relationships between Immune-Mediated Inflammatory Diseases and Hodgkin's Lymphoma: A Mendelian Randomization Study
Junyun Yuan，山东省立医院
3075Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study
Zheng Yan，郑州大学附属肿瘤医院
3076Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study
喻经纬，天津医科大学肿瘤医院
3086High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study
Liqin Ping，中山大学肿瘤防治中心（中山大学附属肿瘤医院）
3089A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
朱军，北京大学肿瘤医院
3091Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL
Yige Shen，上海交通大学医学院附属瑞金医院
3114The Construction of Novel Risk Scores in Diffuse Large B-Cell Lymphoma with Diabetes and the Identification of Glycosylation-Related Prognostic Biomarkers
Wenyue Sun，山东省立医院
3131Metabolic Tumor Volume from Baseline PET/CT Improves Stratification in the High IPI Risk Patients with Diffuse Large B‐Cell Lymphoma
Zhang Hanzhen，南方医科大学南方医院
3134Efficacy and Safety of BTK Inhibitors in Vitreoretinal Lymphoma: A Single-Center, Retrospective Analysis of 24 Patients
王亮，首都医科大学附属北京同仁医院（北京同仁医院）
3137Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）
Lili Zhou，上海市同济医院（同济大学附属同济医院）
3139A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma
李文斌，首都医科大学附属北京天坛医院
3155Genetic Evolution from Chronic Myeloproliferative Neoplasms to Acute Myeloid Leukemia: An Analysis of Forty-Six Paired Samples
Hung Chang，台湾桃园长庚大学
3167A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia
张小帅，北京大学人民医院
3171Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib
Li Weiming，华中科技大学同济医学院附属协和医院
3175Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An Open-Label, Multi-Center Study
许娜，南方医科大学南方医院
3197Adult Langerhans Cell Histiocytosis with Liver Involvement
Long Chang，北京协和医院
3201Efficacy of Demethylated Drug Combine with Low Dose Chemotherapy in Juvenile Myelomonocytic Leukemia
Wenyu Yang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
3221Multi-Omics Reveals Azacitidine Partially Restores Hematopoiesis-Supportive Functions in Mesenchymal Stromal Cells from Patients with Chronic Myelomonocytic Leukemia
Ruohao Xu，广东省人民医院
3315Disruption of DNA-PK-Mediated Cgas Retention on Damaged Chromatin Potentiates Doxorubicin-Induced Cgas/Sting-Dependent Anti-Multiple Myeloma Activity
Jinna Zhang，浙江大学医学院附属第一医院
3338RAB22A As a Predictor of Exosome Secretion in the Progression and Relapse of Multiple Myeloma
王季石，贵州医科大学附属医院
3371The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Mulitiple Myeloma
薛华，河北大学附属医院
3388Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study
傅卫军，上海长征医院（现单位：同济大学附属上海市第四人民医院）
3400A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis
何冬花，浙江大学医学院附属第一医院
3434Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma
Lixia Ma，北京高博博仁医院
3442Developing "Off-the-Shelf" CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia
Li Zhou，合源生物
3451Mitochondrial Isocitrate Dehydrogenase Inhibition Enhances CAR T-Cell Function By Restraining Antioxidant Metabolism and Histone Acetylation
Xiaohui Si，浙江大学医学院附属第一医院
3453As Fast As We Can: Rational Design of Rapid Chimeric Antigen Receptor T Cell Manufacturing
Pengfei Jiang，上海恒润达生生物科技股份有限公司
3466Long-Term Follow-up of Humanized and Murine CD19 CAR-T Cell Therapy for B-Cell Malignancies
Yinqiang Zhang，华中科技大学同济医学院附属协和医院
3468CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
徐旸，浙江大学医学院附属第二医院
3471Phase I Clinical Study of PA3-17 Injection in Patients with Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
黄晓军，北京大学人民医院
3472Safety and Efficacy of GPRC5D CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients
Shiqi Li，中国人民解放军联勤保障部队第九二〇医院
3477Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China
Lei Yu，上海优卡迪生物医药科技有限公司
3480CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Retrospective Study
潘静，北京高博博仁医院
3481Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich" Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
薛胜利，苏州大学附属第一医院
3482Comparison of Efficacy and Side Effects of BTK Inhibitors for Different Duration As a Bridging Therapy before Anti-CD19-CAR T-Cell Therapy in Patients with R/R DLBCL
Rui Cui，天津市第一中心医院
3484Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement
Bailin He，南方医科大学南方医院
3485A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation
Jingjing Feng，浙江大学医学院附属第一医院
3486Sequential Umbilical Cord Derived Mesenchymal Stromal Cells (MSCs) for the Third-Line Salvage Treatment of Steroid-Refractory Acute GvHD: A Multicenter, Open Label, Phase 1b/2 Trial
赵妍敏，浙江大学医学院附属第一医院
3488Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL
涂三芳，南方医科大学珠江医院
3489Phase I Clinical Study of Humanized BCMA-Single-Domain Antibodies-Targeting CAR T (BCMA-CART) in Patients with Relapsed/Refractory Multiple Myeloma
郑高锋，浙江大学医学院附属第一医院
3491Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia
唐晓文，苏州大学附属第一医院
3492Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
涂三芳，南方医科大学珠江医院
3513Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies
Teng Xu，北京高博博仁医院
3515CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations
Bin Xue，上海市同济医院（同济大学附属同济医院）
3524Diverse Effects of Cryopreservation-Induced Mitochondrial Dysregulation on Cord Blood Cells
Yaojin Huang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
3531A Novel Prediction Model for BK Virus Associated Hemorrhagic Cystitis in Acute Leukemia Patients Following Allogenic Hematopoietic Cell Transplantation: A Retrospective Cohort Study
Xueqi Li，北京大学人民医院
3532A Novel Post-Transplant Regimen for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-Cord Transplantation in Childhood Leukemia: A Single-Arm, Dual-Center Trial
Yongsheng Ruan，南方医科大学南方医院
3538Granulocyte Colony-Stimulating Factor and Decitabine-Containing Conditioning Improves Survival in Myelodysplastic Syndrome Patients with Iron Overload Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Wenshu Zhao，南方医科大学南方医院
3539Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial
冯一梅，陆军军医大学第二附属医院（新桥医院）
3540The Therapeutic Efficacy and Blood Drug Concentration of Posaconazole Enteric-Coated Tablets in Preventing Pulmonary Invasive Fungal Disease after HSCT
姜尔烈，中国医学科学院血液病医院（中国医学科学院血液学研究所）
3544Memory T Cell Donor Lymphocyte Infusion As a Treatment for Viral Reactivations after Pediatric Haploidentical Hematopoietic Stem Cell Transplant
Wing H. Leung，香港儿童医院
3547Effectiveness of In Vivo T-Cell Depleted Regimen Containing Porcine Antilymphocyte Globulin and Rabbit Antithymocyte Globulin in Preventing Acute Gvhd after Haploid Hematopoietic Stem Cell Transplantation
Ziwei Xu，华中科技大学同济医学院附属协和医院
3554A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial
邱慧颖，上海市第一人民医院
3556A Prospective, Multi-Center, Randomized, Controlled Clinical Trial to Explore the Role of Mesenchymal Stem Cells in Preventing Graft Versus Host Disease
Han Yao，陆军军医大学第二附属医院（新桥医院）
3565Mesenchymal Stromal Cell Infusion Might Improve Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation and Modulate Alveolar Macrophages in Mice
Ruoyang Shao，南方医科大学南方医院
3568Combining Low-Dose Post-Transplant Cyclophosphamide(PTCY) with Anti-Thymocyte Globulin(ATG) for Prophylaxis of Graft-Versus-Host Disease in Alternative-Donor Hematopoietic Stem Cell Transplantation for β-Thalassemia Major
鹿全意，厦门大学附属中山医院
3569Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Chronic Steroid-Refractory Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation
Fen Huang，南方医科大学南方医院
3579IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms
Tingting Yang，浙江大学医学院附属第一医院
3597Upfront Autologous Stem Cell Transplant at First Complete Remission in Patients with Advanced-Stage Extra-Nodal NK/T Cell Lymphoma: A Multicenter Retrospective Study
胡少轩，北京大学肿瘤医院
3602Efficacy and Safety of Chidamide Combined with BEAM Conditioning Regimen in Autologous Transplantation for T-Cell Lymphoma
Yige Shen，上海交通大学医学院附属瑞金医院
3611A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation
曹星玉，北京陆道培医院
3613Long-Term Outcome of a Unique Haploidentical High-Dose Peripheral Stem Cell Transplantation Protocol for Hematologic Malignancies: A Prospective Single-Center Study
江明，新疆医科大学第一附属医院
3615One-Stop No-Edited Allogenic CAR-T Therapy Bridging HSCT to Treat Children with Relapse and Refractory Acute Lymphoblastic Leukemia: A Prospective Clinical Study from a Single Center
Chengjuan Luo，上海交通大学医学院附属上海儿童医学中心
3619Analysis of Post-Transplant Clinical Outcomes and Prognostic Factors in FLT3-ITD Mutated Acute Myeloid Leukemia Patients Under ELN 2022 Risk Stratification
Chen Liang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
3620MRD Positivity Was the Poor Prognostic Factor for Adverse-Risk AML Patients with Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Trohpy Study
曹阳，华中科技大学同济医学院附属同济医院
3636Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
宋玉琴，北京大学肿瘤医院
3640Pre-Clinical Evaluation of a New-Generation Orally Bioavailable Dual Bcl-2/Bcl-Xl Inhibitor LP-118 in Mantle Cell Lymphoma
Bing Dai，广州麓鹏制药有限公司
3810Projected Global Trends in Hematological Malignancies: Incidence, Mortality, and Disability-Adjusted Life Years from 2020 to 2030
安倬玉，北京大学人民医院
3821Intracerebral Hemorrhage Leads to Anemia By Disrupting Erythropoiesis and Erythromyeloblastic Islands
Shijie Zhang，郑州大学
3825STK10 Mutation Block Erythropoiesis in Acquired Pure Red Cell Aplasia Via Down-Regulated the Ribosome Biosynthesis
Zhangbiao Long，安徽医科大学第一附属医院
3829Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial
陈苗，北京协和医院
3834AURKA Kinase Controls Erythroblast Enucleation Via Regulation of Centrosome Localization and ECT2 Degradation
Yuanlin Xu，郑州大学
3906Single-Cell RNA Sequencing Reveals Contradictory Immune Microenvironment in Hemophagocytic Syndrome
Guo Qiu，南方医科大学南方医院
3915CD10-CD14-hla-DR-CD45 SSC Neutrophils with G-MDSC-like Feature Relate to Progress and Poor Prognosis in Non-Hodgkins Lymphoma Patients
Ji Zhou，安徽医科大学
3918Beneficial Role of Erythrocyte Sphingosine 1-Phosphate in Preventing Renal Macrophage Polarization and Fibrosis through Combating HIF-1α-Dependent Creatine Phosphate Shuttle
Tingting Xie，中南大学湘雅医院
3923G-CSFR Is a Checkpoint of Natural Killer Cells Against Tumor
Xunhong Cao，北京大学人民医院
3926Influenza Training of Granulopoiesis Promotes Long-Term Anti-Leukemia Activity
尤良顺，浙江大学医学院第一附属医院
3929Risk Factors for Omicron Pneumonia in Patients with Hematological Malignancies: A Multicenter Study in China
Li Jun，重庆大学附属肿瘤医院
3940ATRA Can Correct Impaired Proplatelet Formation By Regulating HIF-1α/SPHK2/S1P Axis in ITP
皇秋莎，北京大学人民医院
3942Anti-GPIb/IX Autoantibodies Are Associated with Poor Response to Dexamethasone Combined with Rituximab Therapy in Primary Immune Thrombocytopenia Patients
Bingjie Ding，河南省肿瘤医院
3951Biomarker MSC-C5b-9-Guided Master Therapies for Resistant/Recurrent ITP: A Prospective, Randomized, Open-Label, Multicenter Trial
Menglin Li，北京大学人民医院
3970Efficacy of Hetrombopag in Treatment of Cancer Therapy-Induced Thrombocytopenia in Lymphoma and Multiple Myeloma Patients
陈俊丽，解放军总医院第五医学中心
3981First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Factor XI Monoclonal Antibody SHR-2004 in Healthy Subjects
李娟，南京鼓楼医院
3987The Correlation of Muscle Mass and Walking Distance with Joint Health and Functional Status in Hemophilic Arthropathy Among People with Hemophilia a (PwHA)
Chia-Yau Chang，台北医学大学
3988Low-Dose Immune Tolerance Induction Therapy for Severe Hemophilia a Inhibitor Patients: Immunosuppressants Improve Outcomes but Are Generally Not Necessary for Inhibitor-Titer below 200 BU/Ml
Zhengping Li，首都医科大学附属北京儿童医院
3995A Single-Center Study of Patients with Isolated Acquired Clotting Factor Deficiency: Clinical Features, Treatments, and Prognosis
Dandan Yu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4035Identification of Anti-HLA-C Autoantibody As Risk Factor for Primary Platelet Transfusion Refractoriness in Patients with Hematologic Disorders
Qi Liu，浙江省中医院
4057New Insights into Hematopoietic Redefinition and New Paradigms in Hematopoietic Hierarchy Roadmap
Yongjian Yue，深圳市人民医院
4058ELTD1 Suppression Enhances Human Embryonic Stem Cell Hematopoiesis By Facilitating Hemogenic Endothelial Progenitor Induction Via Wnt/β-Catenin Signaling Inhibition
Qian Luo，浙江大学医学院第一附属医院
4086IST Combined with Full-Dose Rhtpo in the Treatment of Severe Aplastic Anemia -a Prospective Single-Center Clinical Study
樊慧慧，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4087Avatrombopag Is Effective in First-Line Treatment of Severe Aplastic Anemia: Early Outcomes of a Prospective Study
赵馨，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4091Avatrombopag in Combination with Immunosuppressive Therapy for Hepatitis-Associated Aplastic Anemia
杨文睿，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4115Targeting NUP214 Eradicates Leukemia Stem Cells By Inducing Ferroptosis
侯宇，重庆医科大学
4122Phase Separation Mediates RUNX1- Mutation Leukemic Transformation
Xiuhua Su，山东大学齐鲁医院
4123Novel Fusion Gene Aven-NUTM1 Induces Mice Myeloid Leukemia Vulnerable to HDAC Inhibitors
Yuqing Dan，上海交通大学医学院附属瑞金医院
4129AML1-ETO and CCND2 Overexpression­ Cooperate to Drive AML Initiation and Progression
Junli Mou，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4130RNA-Binding Protein RBM5 Plays an Essential Role in Acute Myeloid Leukemia By Activating the Oncogenic Protein HOXA9
Mengli Zhang，苏州大学
4131Combination of Decitabine and Etoposide Is Highly Effective in Treating p53-Mutated MDS/AML Via Activating Notch Signaling
马洁娴，复旦大学附属华东医院
4132UBC9 Deficiency Accelerates AML Progression By Downregulating PARP1 Sumoylation and Subsequently Activating the NF-ΚB Pathway
Jing Zhou，华中科技大学同济医学院附属协和医院
4134SUMO E3 Ligase ZMIZ1 Drives Leukemogenesis Via Transcriptional Deregulation in Acute Myeloid Leukemia
Fu Ziyu，上海交通大学医学院附属瑞金医院
4148Ubiquitin-Mediated Degradation of MORF4L1 By FBXO11 Suppresses Cholesterol Biosynthesis in T Cell Acute Lymphoblastic Leukemia
Peng Xu，苏州大学唐仲英医学研究院
4150Lncrna Famlf-2 Promotes Leukemogenesis Via the DHX9/c-Myc Axis in Acute Lymphoblastic Leukemia
赖小林，福建医科大学附属协和医院
4161Synergistic Activity of Adefovir Dipivoxil and Venetoclax to Target the Bioenergetic Metabolism of Acute Myeloid Leukemia
Xubo Gong，浙江大学医学院附属第二医院
4164Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia
Moran Wang，华中科技大学同济医学院附属协和医院
4188Dual Targeting Novel WDR5/ATAD2 Oncogenic Signaling through CK2/Ikaros Axis Demonstrates Synergistic Efficacy in T-ALL
葛峥，东南大学附属中大医院
4205Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
许改香，浙江大学医学院第一附属医院
4207Dynamic Changes in ABL1 Kinase Domain Mutations and Comparative Efficacy of Third-Generation Tyrosine Kinase Inhibitors across Different Stages in Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Blast Crisis Patients
洪梅，华中科技大学同济医学院附属协和医院
4209The Impact of ZNF384 Rearranged on Antigen Editing during Treatment-Specific Selective Pressures in Adult B Cell Acute Lymphoid Leukemia
顾闰夏，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4216RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosed adult AML: A Retrospective Study of Chinese AML Patients
薛胜利，苏州大学附属第一医院
4226Assessment of 2022 European Leukemianet Risk Classification System in FLT3-ITD Positive Real-World Cohort from China
Enbo Chen，安徽医科大学第一附属医院
4237A Prognostic Score Model for Relapsed/Refractory Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation
金悦，北京大学人民医院
4241Evaluation of the Effectiveness of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia during Induction Chemotherapy
Yang Zhou，南方医科大学南方医院
4243Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study
Jing Lu，苏州大学附属第一医院
4252The Topoisomerase-I Inhibitor Gimatecan Exhibits Potent and Selective Activities Against B-Cell Precursor Acute Lymphoblastic Leukemia with a Favorable Cardiotoxicity Profile
Han Wang，香港中文大学
4253CRM1/XPO1-FOXO1 Pathway Is Associated with Clinical Outcome and Represents a Promising Target in B-Cell Acute Lymphocytic Leukemia
Shiyu Deng，南方医科大学南方医院
4262Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study
余国攀，南方医科大学南方医院
4263Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial
黄睿，南方医科大学珠江医院
4266Myelomonocytic/Monocytic Subtypes Are More Resistant to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients: A Monocentric, Real-Life Retrospective Study
吴俣，四川大学华西医院
4272Venetoclax Combined with Homoharringtonine and Cytarabine ( HAV) As Induction Treatment in Elder or Intensive Chemotherapy (IC) Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia
Kaiqi Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4274Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia
Jie Zha，厦门大学附属第一医院
4276A Multicenter Clinical Study with Reduced Intensive Chemotherapy for Induction Remission of Pediatric Acute Megakaryoblastic Leukemia
Yixin Hu，苏州大学附属儿童医院
4280A Phase 1b Study Evaluating the Safety and Efficacy of AK117 (anti-CD47 monoclonal antibody) in Combination with Azacitidine in Patients with Treatment-Naïve Acute Myeloid Leukemia
金洁，浙江大学医学院第一附属医院
4281Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study
金洁，浙江大学医学院第一附属医院
4288A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy
唐菲菲，北京大学人民医院
4291Childhood AML Combined with AML1-ETO Fusion Gene and c-KIT or Other Mutations Had Favorable Survival Treated By the C-Huanan AML 2015 Protocol: Study in Multicenter of South of China
冯晓勤，南方医科大学南方医院
4309Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival
Wenbing Duan，北京大学人民医院
4323MPO and Trh within Leukemia Stem Cells Increased Chemosensitivity in Acute Myeloid Leukemia: A Single-Cell RNA Sequencing Approach
Chieh-Lin Jerry Teng，台中荣民总医院
4331Genomic Landscape of Pediatric Non-Down's Syndrome Acute Megakaryoblastic Leukemia in China
Kefei Wu，上海交通大学医学院附属上海儿童医学中心
4335All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling
陈苏宁，苏州大学附属第一医院
4343UHRF1-Mediated Epigenetic Reprogramming Regulates Glycolysis to Promote Progression of B-Cell Acute Lymphoblastic Leukemia
胡建达，福建医科大学附属第二医院
4348JAK2 Kinase Fusion and Myeloid Involvement in Acute Lymphoblastic Leukemia
王彤，北京陆道培医院
4363NCAPD3 Prompts Diffuse Large B-Cell Lymphoma Progression through Modulating SIRT1 Expression in H3K9 Monomethylation-Dependent Manner
Tiange Lu，山东省立医院
4368Proteogenomic Features Define Novel Subtypes of Mantle Cell Lymphoma
Yuting Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4372Validation of Circulating Tumor DNA As an Alternative to Tumor Tissue Biopsy in Genotyping across Multiple Lymphoma Subtypes
刘海生，河北医科大学第四医院
4387The Correlation between Alterations in the Intestinal Microbiome and Early Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B-Cell Lymphoma
盛立霞，宁波大学附属第一医院
4388The Characterization and Prognostic Value of Tumor Immune Microenvironment in Diffuse Large B-Cell Lymphoma
Bingyu Liu，山东省立医院
4400A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton’s Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
宋玉琴，北京大学肿瘤医院
4411Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study
黄慧强，中山大学肿瘤防治中心（中山大学附属肿瘤医院）
4416Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma
Yingtong Chen，北京大学第三医院
4417Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis
高凤华，天津医科大学肿瘤医院
4418Spectrum and Clinical Features of Gene Mutations in Chinese Follicular Lymphoma
Chunyuan Li，北京大学第三医院
4423Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)
杨萍，北京大学第三医院
4427A Retrospective Analysis on the Efficacy and Saftey of Obinutuzumab in the Treatment of Non-Hodgkin B Cell Lymphoma
Yangzhi Zhao，吉林大学白求恩第一医院
4428A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies
金洁，浙江大学医学院第一附属医院
4430Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)
金洁，浙江大学医学院第一附属医院
4445Clinical Significance of Serum High-Density Lipoprotein Cholesterol and Its Dynamic Change in Patients with Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
施文瑜，南通大学附属医院
4447Clinical Observation of Camrelizumab (CAM) Combined with Bendamustine and Gemcitabine (BeGe) in Relapsed/Refractory Classical Hodgkin Lymphoma (cHL): A Phase II Trial
白敏，山西省肿瘤医院
4448Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma:Pathological Phenotype and Genetic Mutation Analysis of 12 Patients
何静松，浙江大学医学院第一附属医院
4458Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas
宋玉琴，北京大学肿瘤医院
4465First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)
宋玉琴，北京大学肿瘤医院
4468Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study
金佳，复旦大学附属肿瘤医院
4469Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
林宁晶，北京大学肿瘤医院
4470Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial
蔡清清，中山大学肿瘤防治中心（中山大学附属肿瘤医院）
4478PET Radiomics Score Generated By Cross-Combination Approach for Treatment Response and Prognosis Prediction in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma Patients
Jincheng Zhao，南京鼓楼医院
4480A Prognostic Nomogram Survival Model for Newly Diagnosed Patients with AIDS-Related Diffuse Large B-Cell Lymphoma: A Multicenter Cohort Study in China
杨涛，重庆大学附属肿瘤医院
4488Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma
Yige Shen，上海交通大学医学院附属瑞金医院
4489Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)
黄爽，首都医科大学附属北京儿童医院
4494Pre-treatment 18f-FDG PET/CT for Assessing and Predicting Bone Marrow Involvement in Patients with Newly Diagnosed Peripheral T-Cell Lymphoma
Jing Chen，浙江大学医学院第一附属医院
4506PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis
杨海燕，浙江省肿瘤医院
4507The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors
Hui SHI，北京高博博仁医院
4519The Function and Mechanism Research of NLRP6 in Bone Marrow Microenvironment in Myeloproliferative Neoplasms
Yanjie Li，徐州医科大学附属医院
4538Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study
许娜，南方医科大学南方医院
4545Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival
黄励思，广东省人民医院
45503rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2nd Chronic Phase Able to Receive a Transplant
Mei Bao，北京大学人民医院
4562Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification
Harinder Gill，香港大学
4577Comparative Analysis of Bone Marrow Microbiome and Proteome Differences between Essential Thrombocythaemia and Prefibrotic Primary Myelofibrosis
Anqi Zhang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4578The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients：the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study
段明辉，北京协和医院
4594The Molecular Prognostic Scoring System for Normal Karyotype Myelodysplastic Syndromes
佟红艳，浙江大学医学院第一附属医院
4598A Clinical-Molecular Prognostic Scoring System for Myelodysplastic Syndrome in Asia – a Multicenter Study of the Asian Myeloid Working Group (AMWG)
Harinder Gill，香港大学
4600Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study
王婧，北京大学人民医院
4614High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations
佟红艳，浙江大学医学院第一附属医院
4617Azacitidine Combination with Lenalidomide in Treating Higher-Risk Myelodysplastic Syndromes: A Single-Center, Phase 2 Trial
葛峥，东南大学附属中大医院
4628PRMT1 Promotes Chronic Lymphocytic Leukemia Progression Via Modulating Methylation of MAST1
Zheng Tian，山东省立医院
4638A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter’s Transformation
冯少美，北京高博博仁医院
4642Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
朱华渊，江苏省人民医院
4653A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma
朱华渊，江苏省人民医院
4661Enhanced Expression of DNp73 Promotes Drug Resistance and Immune Evasion in Multiple Myeloma By Targeting the MYC and MYCN Pathways
Lanting Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4667Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in MRD Clones in Multiple Myeloma through Single-Cell Sequencing
崔健，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4672Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma
Hong Ling，南京维立志博生物科技有限公司
4673CRIP1 Upregulated Along with chr1q-Gain Indicates Immune Dysregulation and Portends Poor Outcomes in Multiple Myeloma
Shanshan Zhang，南方医科大学南方医院
4674Targeting RBM39-MEK5 Axis Synergizes with Bortezomib to Inhibit Multiple Myeloma Malignancy
Jia Liu，上海交通大学医学院附属瑞金医院
4679Identification of LPAR1/LPAR5 As Novel GPCR Partners of GPRC5D for the Efficient CAR-T Therapy of Multiple Myeloma
Xinyi Zhou，上海长征医院
4691Cells of the Osteoblast Lineage Cross-Talk with Myeloid‑Derived Suppressor Cells to Promote Multiple Myeloma Growth
Xiaoxuan Xu，广州市第一人民医院
4695MASS-4 Is More Suitable Than MASS-3 for Prognostic Stratification in Transplant-Eligible Patients Withnewly Diagnosed Multiple Myeloma
李娟，中山大学附属第一医院
4725CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array
Zhao Zeng，苏州大学附属第一医院
4726The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study
Shuchan Li，浙江大学医学院附属第一医院
4732Survival Trends and Prognostic Factors of Patients with Newly Diagnosed Multiple Myeloma Accompanied with Extramedullary Disease
Jing Wang，江苏省人民医院
4740Combination of Circulating Plasma Cells Enhances the Efficacy of R2-ISS Stage System for Risk Stratification of Newly Diagnosed Multiple Myeloma: A Single-Center Real-World Study
Bin Chu，北京积水潭医院
4754Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
高文，北京朝阳医院
4763Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma
孙春艳，华中科技大学同济医学院附属协和医院
4789Single-Cell Transcriptional Survey of the Initiation, Propagation and Maintenance of the Intestinal Graft-Versus-Host Disease
Fei Gao，浙江大学医学院附属第一医院
4792Itaconate Inhibits Th1 Differentiation and aGVHD Via Nrf2
沈耀耀，苏州大学附属第一医院
4794HIF-1α-Dependent Autophagy Deficiency in Bone Marrow Endothelial Progenitor Cells Contributes to Acute Graft-Versus-Host Disease after Allotransplant
Wenkai Zhang，华中科技大学同济医学院附属协和医院
4798Recipient Resident Macrophage Plays a Crucial Role in Acute Graft-Versus-Host-Disease after Allogeneic Stem Cell Transplantation By Regulation of Damage-Associated Molecular Pattern Phagocytosis
Yuyan Shen，中国医学科学院血液病医院（中国医学科学院血液学研究所
4802Efficacy of Human iPSC-Derived CAR-NK Cells Targeting Multiple Myeloma Cells
杨佳银，深圳市三启生物技术有限公司
4810Gp350-Targeted CAR-T Therapy in EBV-Positive NK/T-Cell Lymphoma: Pre-Clinical Development of gp350CAR-T
Zhimai Gao，安徽医科大学第二附属医院
4823Autophagy Inhibition Prevents CAR-T Exhaustion and Terminal Differentiation Via TCF7 Accumulation
滕心怡，浙江大学医学院附属第一医院
4835CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study
冯晶晶，浙江大学医学院附属第一医院
4837Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study
王迪，华中科技大学同济医学院附属同济医院
4841Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Langqi Wang，南方医科大学珠江医院
4843Efficacy and Safety of CD19-Specific CAR-T Cell Therapy Following Immunochemotherapy in Newly Diagnosed B-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis
周玉兰，南昌大学第一附属医院
4844Efficacy and Safety of BCMA-Specific CAR T Cell-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients with Extramedullary Disease
Yuekun Qi，徐州医科大学附属医院
4845Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma
傅琤琤，苏州大学附属第一医院
4851Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients
Zongcheng Li，中国人民解放军总医院第五医学中心
4854Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma
王迪，华中科技大学同济医学院附属同济医院
4871Adoptive Therapy with Cytomegalovirus-Specific Cytotoxic T Lymphocytes for Refractory Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Zhonghui Jiang，南方医科大学南方医院
4890Constructing a Machine Learning-Based Rating Model to Predict the Outcome of GCSF Mobilization of Hematopoietic Stem Cells in Peripheral Blood
Xiangjun Zeng，浙江大学医学院附属第一医院
4891The Combination of Pegfilgrastim and Filgrastim Improves the Outcomes of Mobilization and Engraftment after Transplantation of Autologous Hematopoietic Stem Cells for the Treatment of Lymphoma
Xingtong Wang，吉林大学第一医院
4903Efficacy of Venetoclax Combined with Decitabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk and Elderly Patients with Myeloid Neoplasms
Xinhui Zheng，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4906Myeloablative Fractionated Busulfan Conditioning Regimen with Chidamide in Patients with AML/MDS Less Than Complete Remission
徐娟，四川大学华西医院
4909Venetoclax Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes
QI Tan，苏州大学附属第一医院
4913Humanized Anti-CD25 Monoclonal Antibody Replacing MTX for Graft-Versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation
Zhenli Huang，华中科技大学同济医学院附属协和医院
4922Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
乔曼，苏州大学附属第一医院
4923MSCs-IL33-ILC2s-AREG-Tecs Axis Promotes the Remodeling of Thymic Function in Acute Gvhd
Jia-Bao He，南方医科大学南方医院
4929Clinical Study on Cytokines Panel in the Diagnosis of Ocular Chronic Graft-Versus-Host Disease
Xianjing Cheng，陆军军医大学第二附属医院（新桥医院）
4939Double-Negative T Cells Attenuate Acute Graft-Versus-Host Disease By Modulating CD4 T Cell Activation Post-Allo-HSCT
Tianzhong Pan，中国科学技术大学附属第一医院（安徽省立医院）
4946Pathophysiology and Treatment Opportunities of CX3CL1 in Liver Acute Gvhd
Ziwei Xu，华中科技大学同济医学院附属协和医院
4951A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study
周建英，北京大学人民医院
4952Venetoclax Plus Azacitidine Versus Azacitidine Alone As Post-Transplant Maintenance Treatment in High-Risk AML and MDS
曹易耕，中国医学科学院血液病医院（中国医学科学院血液学研究所）
4953A Novel Protocol Improves Engraftment in Tαβ Cell Depleted Haplo-HSCT for Patients with Thalassemia Major
李春富，台心医院&南方春富（儿童）血液病研究院
4986A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
叶逸山，浙江大学医学院附属第一医院
4991Maintenance Therapy with Chidamide Plus Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia Patients
胡晓慧，苏州大学附属第一医院
4994Safety and Efficacy of RM-001 (Autologous HBG1/2 Promoter-modified CD34 Hematopoietic Stem and Progenitor Cells) in Patients with Transfusion-Dependent β-Thalassemia
Hui Xu，广州瑞风生物科技有限公司
4995Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia
郑彪，上海邦耀生物科技有限公司
4998Gene Therapy of Transfusion-Dependent β-Thalassemia Patients with Quick Engraftment of Reinfused Hematopoietic Stem Cells: An Investigator-Initiated Trial of KL003
黄金棋，广东医科大学附属医院
5001Prime Editing of the α-Thalassemia Hb Constant Spring Mutation
Qing Liu，南方医科大学
5005Adding Hetrombopag to Cyclosporine a to Patients with Newly Diagnosed Transfusion-Dependent Non-Severe Aplastic Anemia—a Prospective Phase 2 Study
申舒培，北京协和医院
5010STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3-Mutated (mut) Acute Myeloid Leukemia (AML)
张仪，浙江大学医学院附属第一医院
5019Machine Learning-Facilitated Cross-Panel Automatic Classification at Both Sample and Cell Level in Acute Myeloid Leukemia
Yu-Fen Wang，先劲智能有限公司（台湾）
5020Diagnostic Performance and Clinical Impacts of Metagenomic Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation
徐春晖，中国医学科学院血液病医院（中国医学科学院血液学研究所）
5103Effect of Pre-Transplantation Nutritional Status on the Early Related Complications of Allogeneic Hematopoietic Stem Cell Transplantation:a Cohort Study
吴芳芳，陆军军医大学第二附属医院（新桥医院）
5168Improved Survival with Rituximab-Based Chemoimmunotherapy in Patients with Primary Testicular Diffuse Large B-Cell Lymphoma
Shengli He，复旦大学附属肿瘤医院闵行分院

排名不分先后，按照摘要号进行排序如有遗漏或任何问题，请给我们留言~

排版：Moly

执行：Eve

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。